GSK-4527363

N/A

Report date: 2025/12/19 17:16:39
NME

Base Information

Drug NameGSK-4527363
Drug Alias NameGSK4527363GSK-4527363
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionB cells modulators
TargetsUpdating
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandArgentina +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A